These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34957531)

  • 41. The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.
    Cameli P; Alonzi V; d'Alessandro M; Bergantini L; Pordon E; Guerrieri M; Refini RM; Sestini P; Bargagli E
    Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
    Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
    Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.
    Wijsenbeek M; Swigris JJ; Inoue Y; Kreuter M; Maher TM; Suda T; Baldwin M; Mueller H; Rohr KB; Flaherty KR;
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38135442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.
    Swigris JJ; Bushnell DM; Rohr K; Mueller H; Baldwin M; Inoue Y
    BMJ Open Respir Res; 2022 Mar; 9(1):. PubMed ID: 35241434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Mazzei ME; Richeldi L; Collard HR
    Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics.
    Kolb M; Flaherty KR; Silva RS; Prasse A; Vancheri C; Mueller H; Sroka-Saidi K; Wells AU;
    Adv Ther; 2023 Dec; 40(12):5536-5546. PubMed ID: 37751022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis.
    Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M
    Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease.
    Yamakawa H; Sato S; Ohta H; Kusano K; Kawabe R; Oba T; Uzuka C; Sasaki H; Akasaka K; Amano M; Takemura T; Araya J; Matsushima H
    Respir Investig; 2024 Jul; 62(4):551-557. PubMed ID: 38663299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
    Shumar JN; Chandel A; King CS
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
    Chen CH; Lin HC; Wang YH; Wang CY; Lin YS; Lai CC
    PLoS One; 2021; 16(5):e0251636. PubMed ID: 33989328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis.
    Rochwerg B; Neupane B; Zhang Y; Garcia CC; Raghu G; Richeldi L; Brozek J; Beyene J; Schünemann H
    BMC Med; 2016 Feb; 14():18. PubMed ID: 26843176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
    de Lauretis A; Veeraraghavan S; Renzoni E
    Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
    Popmihajlov Z; Sutherland DJ; Horan GS; Ghosh A; Lynch DA; Noble PW; Richeldi L; Reiss TF; Greenberg S
    BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35058236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
    Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
    Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
    Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
    Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.